Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has signed a pair of licensing agreements with Korean biopharmaceutical company BIOA&D Co. Ltd. The first relates to the use of Crucell’s PER.C6® technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of cardiovascular disease. In addition, the parties have signed an agreement that allows BIOA&D to use Crucell’s patented ceNOS gene therapy technology.
